Italian competition authorities announced Wednesday they have launched an investigation into pharmaceutical company Biogen and its Italian subsidiary over accusations of market dominance abuse.
According to regulators, both companies are suspected of working to prevent competitor Sandoz from marketing multiple sclerosis treatments containing the active ingredient natalizumab.
Officials conducted searches at Biogen’s Italian headquarters with assistance from Italy’s financial police, the regulatory agency reported.
Company representatives from Biogen could not be reached for immediate response to the allegations.
